首页|沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗扩张型心肌病的效果分析

沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗扩张型心肌病的效果分析

扫码查看
目的 研究沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗扩张型心肌病(dilated cardiomyopa-thy,DCM)的效果.方法 目的选取2021年12月—2023年12月盐城市第一人民医院收治的DCM患者118例,根据治疗药物不同分为观察组(沙库巴曲缬沙坦钠片+琥珀酸美托洛尔缓释片)和对照组(单独用琥珀酸美托洛尔缓释片),每组59例,对比两组患者用药后的疗效、心肌损伤情况、左室功能、运动耐量情况.结果 观察组总有效率为96.61%(57/59)高于对照组的84.75%(50/59),差异有统计学意义(χ2=4.912,P<0.05).治疗后,观察组心肌损伤情况低于对照组,差异有统计学意义(P均<0.05).观察组左心室射血分数高于对照组,左心室舒张末期体积、左心室收缩末期体积、左心房直径低于对照组,差异有统计学意义(P均<0.05).观察组运动耐量高于对照组,差异有统计学意义(P均<0.05).观察组不良反应总发生率低于对照组,差异有统计学意义(P<0.05).结论 采用沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片药物对DCM治疗,可有效的改善患者的心肌损伤情况、心功能以及运动耐量,降低不良反应发生率,疗效较好.
Effect analysis of Sacubitril Valsartan Sodium Tablets Combined with Metoprolol Succinate Extended-release Tablets in the Treatment of Di-lated Cardiomyopathy
Objective To study the effect of sacubitril valsartan sodium tablets combined with metoprolol succinate sustained-release tablets in the treatment of dilated cardiomyopathy(DCM).Methods A total of 118 patients with DCM admitted to Yancheng First People's Hospital from December 2021 to December 2023 were objectively selected and divided into observation group(sacubitril valsartan sodium tablets+metoprolol succinate sustained-release tab-lets)and control group(metoprolol succinate sustained-release tablets alone)according to different drug,with fifty nine cases in each group.The efficacy,myocardial injury,left ventricular function and exercise tolerance of the two groups were compared.Results The total effective rate of the observation group was 96.61% (57/59),which was higher than 84.75%(50/59)of the control group,and the difference was statistically significant(χ2=4.912,P<0.05).After treatment,the myocardial injury in the observation group was lower than that in the control group,and the differences were statistically significant(all P<0.05).The left ventricular ejection fraction of the observation group was higher than that of the control group,and the left ventricular end-diastolic volume,left ventricular end-systolic volume and left atrial diameter were lower than those of the control group,the differences were statistically significant(all P<0.05).The exercise tolerance of the observation group was higher than that of the control group,and the differences were sta-tistically significant(all P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion The treatment of DCM with sacu-bitril valsartan sodium tablets combined with metoprolol succinate sustained-release tablets can effectively improve the myocardial injury,cardiac function and exercise tolerance of patients,reduce the incidence of adverse reactions,and the curative effect is better.

Sacubitril valsartan sodium tabletsMetoprolol succinate sustained-release tabletsDilated cardiomyopathy

马旭、朱成振、许康世

展开 >

盐城市第一人民医院心血管内科,江苏 盐城 224001

沙库巴曲缬沙坦钠片 琥珀酸美托洛尔缓释片 扩张型心肌病

2024

系统医学

系统医学

ISSN:
年,卷(期):2024.9(17)
  • 16